Amneal Pharmaceuticals, Inc. (AMRX): Revenue
$3.02B
Year ended 2025-12-31
$3.12B
Trailing 12 months to 2026-06-30
+10.9%
3-year compound annual growth
+8.7%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.02B | +8.0% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $2.79B | +16.7% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $2.39B | +8.2% | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | $2.21B | +5.7% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $2.09B | +5.1% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $1.99B | +22.5% | 2023-03-03, From 2020-01-01 |
| 2019-12-31 | $1.63B | -2.2% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $1.66B | +60.9% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $1.03B | +1.5% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $1.02B | n/a | 2019-03-01, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $3.02B | +8.0% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $3.18B | +10.6% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $3.22B | +12.9% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $3.71B | +65.2% |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $2.38B | +5.1% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $2.20B | +15.6% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $4.25B | -2.8% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $4.27B | +4.9% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $4.71B | +6.2% |
Compare AMRX, UTHR, BMRN, ALNY side by side · Screen every company in Pharmaceutical Preparations ↗